Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

This non-interventional, prospective study will characterize the impact of three approved
first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and
metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and
initiating first-line TKIs in routine clinical practice in the US. All treatment decisions
will be determined at the discretion of the treating physician(s) and data identifying the
cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples
(collected following 8 hours of fasting) will be collected during standard of care
(SOC)/routine office visits. Additional research imaging will be performed and will be
reviewed by core imaging laboratory. As the study is collecting data on management of CML,
this study will not influence the prescribing or management practices at participating sites.